Sign up
Pharma Capital

Sareum surges as it signals progress on pre-clinical programmes

"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas," said Dr Tim Mitchell, the Sareum CEO.
Drug development
"We are focused on advancing these exciting preclinical candidates towards human trials as quickly as possible, aiming for first-in-man studies to begin in 2020."

Sareum Holdings PLC (LON:SAR), the specialist small molecule drug development business, has hailed the recent progress of its clinical and pre-clinical programmes.

Following last week’s announcement of preliminary efficacy data for SRA737, a cancer drug it helped to develop, the company provided the market with an update on other developments within its active pre-clinical portfolio.

READ Sareum Holdings hails early-stage efficacy data for cancer drug

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation, Sareum said.

Sareum's recent activities have focused on toxicology studies designed to gain insight into the maximum-tolerated doses of SDC-1801 and SDC-1802 in rodents.

SDC-1801, the autoimmune diseases candidate, is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; a maximum tolerated dose has yet to be reached.

In addition, the company has been exploring reliable manufacturing routes to produce each candidate for preclinical and clinical studies; such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.

"We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes,” said Dr Tim Mitchell, the chief executive officer of Sareum.

Shares in Sareum were up 4.8% in early deals.


Why Invest In Sareum Holdings PLC? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile View Profile

Sareum Holdings primed for progress

View All

Related Articles

picture of a knee
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.